Table 1 Clinicopathological characteristics of enrolled patients with stage IA micropapillary non-predominant lung adenocarcinoma before and after PSM
Characteristics | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
Observation (n = 100) | ACT (n = 49) | P value | Observation (n = 43) | ACT (n = 43) | P value | |
Age (years), median (IQR) | 61.5 (52.3–67.0) | 61.0 (52.5–65.0) | 0.540 | 63.0 (51.0–67.0) | 61.0 (54.0–65.0) | 0.681 |
Sex, n (%) | 0.164 | 0.276 | ||||
Female | 57 (57.0) | 22 (44.9) | 16 (37.2) | 21 (48.8) | ||
Male | 43 (43.0) | 27 (55.1) | 27 (62.8) | 22 (51.2) | ||
Smoking history, n (%) | 0.271 | 0.506 | ||||
Non-smoker | 74 (74.0) | 32 (65.3) | 25 (58.1) | 28 (65.1) | ||
Smoker | 26 (26.0) | 17 (34.7) | 18 (41.9) | 15 (34.9) | ||
Surgical procedure, n (%) | 0.584 | 0.394 | ||||
Open | 13 (13.0) | 8 (16.3) | 9 (20.9) | 6 (14.0) | ||
VATS | 87 (87.0) | 41 (83.7) | 34 (79.1) | 37 (86.0) | ||
Resection range, n (%) | 0.195 | 1.000 | ||||
Sublobar resection | 14 (14.0) | 11 (22.4) | 9 (20.9) | 9 (20.9) | ||
Lobectomy | 86 (86.0) | 38 (77.6) | 34 (79.1) | 34 (79.1) | ||
Number of LN dissected, median (IQR) | 9.0 (6.0–15.0) | 9.0 (6.0–13.5) | 0.677 | 8.0 (5.0–12.0) | 9.0 (6.0–13.0) | 0.700 |
Tumor location, n (%) | 0.411 | 0.674 | ||||
RUL | 26 (26.0) | 13 (26.5) | 12 (27.9) | 13 (30.2) | ||
RML | 5 (5.0) | 3 (6.1) | 1 (2.3) | 3 (7.0) | ||
RLL | 32 (32.0) | 9 (18.4) | 10 (23.3) | 7 (16.3) | ||
LUL | 22 (22.0) | 12 (24.5) | 12 (27.9) | 9 (20.9) | ||
LLL | 15 (15.0) | 12 (24.5) | 8 (18.6) | 11 (25.6) | ||
Tumor size (cm), median (IQR) | 2.0 (1.5–2.5) | 2.0 (1.5–2.6) | 0.955 | 2.0 (1.5–2.2) | 2.0 (1.5–2.6) | 0.534 |
Pathological subtype component (%), median (IQR) | ||||||
Micropapillary | 5.0 (5.0–10.0) | 10.0 (5.0–20.0) | < 0.001 | 10.0 (5.0–15.0) | 10.0 (5.0–20.0) | 0.079 |
Papillary | 10.0 (0–60.0) | 5.0 (0–40.0) | 0.268 | 9.0 (0–30.0) | 0 (0–40.0) | 0.879 |
Solid | 0 (0–0) | 0 (0–10.0) | < 0.001 | 0 (0–0) | 0 (0–10.0) | 0.113 |
Acinar | 40.0 (0.8–80.0) | 40.0 (0–80.0) | 0.901 | 70.0 (20.0–90.0) | 40.0 (0–80.0) | 0.228 |
Lepidic | 0 (0–20.0) | 0 (0–10.0) | 0.070 | 0 (0–10.0) | 0 (0–10.0) | 0.751 |
Lymphovascular invasion, n (%) | 0.260 | 1.000 | ||||
No | 96 (96.0) | 44 (89.8) | 40 (93.0) | 39 (90.7) | ||
Yes | 4 (4.0) | 5 (10.2) | 3 (7.0) | 4 (9.3) | ||
Spread through air spaces, n (%) | 0.519 | 0.451 | ||||
No | 82 (82.0) | 38 (77.6) | 31 (72.1) | 34 (79.1) | ||
Yes | 18 (18.0) | 11 (22.4) | 12 (27.9) | 9 (20.9) | ||
pTNM stage, n (%) | 0.387 | 1.000 | ||||
IA1 | 8 (8.0) | 2 (4.1) | 2 (4.7) | 1 (2.3) | ||
IA2 | 48 (48.0) | 29 (59.2) | 25 (58.1) | 25 (58.1) | ||
IA3 | 44 (44.0) | 18 (36.7) | 16 (37.2) | 17 (39.5) | ||